Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Sell Genzyme s SAGE Technology

NEW YORK, Oct 10 – Genzyme Moloecular Oncology said Tuesday that Invitrogen had licensed the exclusive rights to sell its Serial Analysis of Gene Expression technology in standardized reagent kits.

Under the terms of the agreement, Genzyme Molecular Oncology of Framingham, Mass., will receive an upfront payment and royalties on the sale of each SAGE kit. The agreement will also enable Invitrogen to distribute Genzyme Molecular Oncology's proprietary bioinformatics software for analysis of SAGE results.

Recently, a public gene expression database repository for SAGE data (SAGEmap) was produced through the US National Institute of Health's Cancer Genome Anatomy Project and is now capable of accepting submissions of SAGE sequence data from any source. The database currently contains over two million SAGE tags.

In addition to the agreement with San Diego-based Invitrogen, Genzyme has signed SAGE agreements with pharmaceutical and biotechnology companies including Celera, Pfizer, Bayer, Novartis Agricultural Discovery Institute, Affymetrix, Curis, Memorec, and Compugen.

All SAGE users are able to access the public database of SAGE information as well as make comparisons with the proprietary SAGE data available on Compugen's LabOnWeb and from Celera.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more